Presentation
November 06, 2018

Tumor Mutational Burden (TMB) analysis across multiple genomic platforms with considerations for sample type utility and effects on numerical representation

Why Tumor Mutational Burden (TMB)?
Authors: Victor Weigman, Ph.D. and Stephanie Hastings, Ph.D.

In this presentation, you will learn about the impact of various molecular endpoints for facilitating therapeutic selection with considerations to the
patient’s immune response.   Determining the tumor mutational burden (TMB) has increased in adoption as a biomarker but how it is determined and the implications on interpretation are not standardized. We outline conventions for TMB calculation and suggest algorithm approaches and effects across matched samples tested with Exome, targeted
panels, independent of normal samples.  Using colorectal cancer specimens, we demonstrate utility for extending traditional biomarker testing of FFPE into liquid biopsy inclusive of TMB calculation. We also review updates enhancing algorithms calling TMB with tumor tissue only, showing high linearity concordance to paired calls with high reproducibility and RNA-Sequencing, which are novel frontiers in this space and can extend advantage of TMB in datasets and specimens.

Related Services:
Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Microsatellite Instability Assay for Response to Immunotherapy

MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens

Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 11 Immune Landscape Signatures

T-cell Receptor (TCR) Sequencing Assay for Characterization of Adaptive Immune Response

Detects TCRβ and TCRγ clonotypes expressed at the mRNA level

Read More